Neumora Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Neumora Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($236.93M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($243.79M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($235.93M) | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | ($130.90M) | Mar 3, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($241.16M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($263.46M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($252.10M) | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | ($135.87M) | Mar 3, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $176.07M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $200.93M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $142.72M | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | $91.75M | Mar 3, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($206.44M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($182.94M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($163.28M) | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | ($114.90M) | Mar 3, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $117.0K | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | $511.0K | Mar 3, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.05M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $316.97M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $496.20M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $426.23M | Mar 7, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.18M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $29.91M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $27.12M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $29.40M | Mar 7, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.87M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $287.06M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $469.08M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | ($446.85M) | Mar 3, 2025 |
| FY2024 | Dec 31, 2021 | ($325.22M) | Mar 3, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.18B) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($947.22M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($703.43M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($467.51M) | Mar 7, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.53M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $142.15M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $374.04M | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | $240.94M | Mar 3, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.53M | Mar 30, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | (4) | Mar 3, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | (4) | Mar 3, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 174.26M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 161.71M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 158.83M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 32.61M | Mar 7, 2024 |